Abstract
Chronic pain is among the most disabling and costly disorders, with prevalence ranging from 10% to 55%. However, current therapeutic strategies for chronic pain are unsatisfactory due to our poor understanding of its mechanisms. Thus, novel therapeutic targets need to be found in order to improve these patients’ quality of life. PI3K and its downstream Akt are widely expressed in the spinal cord, particularly in the laminae I-IV of the dorsal horn, where nociceptive C and Aδ fibers of primary afferents principally terminate. Recent studies have demonstrated their critical roles in the development and maintenance of chronic pain. In this review, we summarized the roles and mechanisms of PI3K/Akt pathway in the progression of chronic pain through sciatic nerve injury, diabetic neuropathy, spinal cord injury, bone cancer, opioid tolerance, or opioid-induced hyperalgesia.
Keywords: PI3K, Akt, chronic pain, bone cancer pain, neuropathic pain, inflammatory pain, opioid tolerance.
Current Pharmaceutical Design
Title:PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain
Volume: 23 Issue: 12
Author(s): Shu-Ping Chen, Ya-Qun Zhou, Dai-Qiang Liu, Wen Zhang, Anne Manyande, Xue-Hai Guan, Yu-ke Tian, Da-Wei Ye*Deeq Mohamed Omar
Affiliation:
- Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,China
Keywords: PI3K, Akt, chronic pain, bone cancer pain, neuropathic pain, inflammatory pain, opioid tolerance.
Abstract: Chronic pain is among the most disabling and costly disorders, with prevalence ranging from 10% to 55%. However, current therapeutic strategies for chronic pain are unsatisfactory due to our poor understanding of its mechanisms. Thus, novel therapeutic targets need to be found in order to improve these patients’ quality of life. PI3K and its downstream Akt are widely expressed in the spinal cord, particularly in the laminae I-IV of the dorsal horn, where nociceptive C and Aδ fibers of primary afferents principally terminate. Recent studies have demonstrated their critical roles in the development and maintenance of chronic pain. In this review, we summarized the roles and mechanisms of PI3K/Akt pathway in the progression of chronic pain through sciatic nerve injury, diabetic neuropathy, spinal cord injury, bone cancer, opioid tolerance, or opioid-induced hyperalgesia.
Export Options
About this article
Cite this article as:
Chen Shu-Ping, Zhou Ya-Qun, Liu Dai-Qiang, Zhang Wen, Manyande Anne, Guan Xue-Hai, Tian Yu-ke, Ye Da-Wei*, Omar Mohamed Deeq, PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain, Current Pharmaceutical Design 2017; 23 (12) . https://dx.doi.org/10.2174/1381612823666170210150147
DOI https://dx.doi.org/10.2174/1381612823666170210150147 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Lipopolysaccharide-Induced Chorioamnionitis Causes Acute Inflammatory Changes in the Ovine Central Nervous System
CNS & Neurological Disorders - Drug Targets Microglial Senescence
CNS & Neurological Disorders - Drug Targets Exercise-Induced MicroRNA Regulation in the Mice Nervous System is Maintained After Activity Cessation
MicroRNA Current Updates on Bone Grafting Biomaterials and Recombinant Human Growth Factors Implanted Biotherapy for Spinal Fusion: A Review of Human Clinical Studies
Current Drug Delivery Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Glutamatergic Neurotransmission As Molecular Target of New Anticonvulsants
Current Topics in Medicinal Chemistry The Fall in Older Adults: Physical and Cognitive Problems
Current Aging Science The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Current Genomics Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Nerve Growth Factor: Structure, Function and Therapeutic Implications for Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders Neurotrophic Actions of Mood-Stabilizers: A Recent Research Discovery and its Potential Clinical Applications
Current Psychiatry Reviews Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier
Current Pharmaceutical Design HSV Amplicons: Neuro Applications
Current Gene Therapy Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Evaluation of the Radioprotective Effects of Melatonin Against Ionizing Radiation-Induced Muscle Tissue Injury
Current Radiopharmaceuticals A Quantitative Proteomic Analysis to Reveal Effects of N-acetylcysteine on H<sub>2</sub>O<sub>2</sub>-induced Cytotoxicity
Current Proteomics